Iambic raised over $100 million in an oversubscribed financing round to advance AI‑discovered therapeutics and its platform, attracting heavyweight investors including ARK, Regeneron and Illumina Ventures. The financing will support multiple clinical programs and technology scale‑up, following clinical activity for the company’s first AI‑derived molecules. The funding round underscores investor confidence in AI‑driven discovery firms that have moved candidates into the clinic. Iambic intends to push two additional discovery programs toward IND enabling work and pursue partnerships to monetize its modeling and structure‑prediction capabilities.